AMT-562

N/A

Report date: 2024/03/14 17:51:09

Base Information

Drug NameAMT-562
Drug Alias NameAMT-562
ClassificationBiologics > Protein drugs > Immunoglobulin > Antibody > Antibody conjugate > Antibody drug conjugate (ADC)Biologics > Protein drugs > Immunoglobulin > Antibody > Antibody conjugate > Antibody drug conjugate (ADC) > Payload > Exatecan payloadBiologics > Protein drugs > Immunoglobulin > Antibody > Antibody conjugate > Antibody drug conjugate (ADC) > Linker > Cleavable linker > VA linker
Mechanisms of ActionAnti-Receptor tyrosine-protein kinase erbB-3DNA topoisomerase I inhibitors
TargetsReceptor tyrosine-protein kinase erbB-3DNA topoisomerase I
Therapy Area/IndicationsSolid tumoursCarcinoma, Non-Small-Cell LungStomach Neoplasms +[4] 
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited StatesAustraliaMainland China
CombinationsNo
Global Highest StatusPhase 1 Clinical
Highest Status in ChinaPhase 1 Clinical
Originator CompaniesMultitude Therapeutics Inc
China Registration ClassClass 1 therapeutic biologic in China

Develop Information

Active CompaniesMultitude Therapeutics (Australia) Pty LtdPuzhong Discovery Medical Technology (Shanghai) Co LtdMultitude Therapeutics Inc
Inactive CompaniesN/A
Active IndicationsSolid tumoursCarcinoma, Non-Small-Cell LungStomach Neoplasms +[4] 
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A